All In Biotech

Investigational drug · Phase 2

HS-10542

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for IgAN, Immunoglobulin A Nephropathy (IgAN), Glomerular Disease.

Phase 2

Last checked: Nov 19, 2026Latest source record: Apr 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

2

2 still active

All registered trials

3

Any phase or sponsor naming "HS-10542"

First trial start

2026

Feb 14, 2026

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "HS-10542", any sponsor or status.

Conditions studied

As listed on its trial records.

  • IgAN
  • Immunoglobulin A Nephropathy (IgAN)
  • Glomerular Disease
  • Paroxysmal Nocturnal Hemoglobinuria

Approved drugs for the same conditions: Paroxysmal nocturnal hemoglobinuria · IgA nephropathy · Kidney and urology

Largest trials

Live from ClinicalTrials.gov: studies naming "HS-10542" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for IgAN

  • siRNAADX-038, ADX-324Phase 37 trials

    ADARx Pharmaceuticals, Inc. · Hereditary Angioedema, HAE, Hereditary Angioedema - Type 1

  • FXS6837Phase 34 trials

    Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. · Paroxysmal Nocturnal Hemoglobinuria, Primary IgAN, IgAN

  • STL303Phase 22 trials

    Sitala Bio LTD · IgAN, Geographic Atrophy

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.